Overview

Protective Effect of EPA on Cardiovascular Events

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to test the hypothesis that the long-term use of highly (>98%) purified EPA, in addition to HMG-CoA reductase inhibitor (statin), would be more effective than statin alone in preventing cardiovascular events in Japanese patients with hypercholesterolemia.
Phase:
Phase 4
Details
Lead Sponsor:
Kobe University
Collaborator:
Mochida Pharmaceutical Company, Ltd.
Treatments:
Eicosapentaenoic acid ethyl ester